Maryam Tehranipour | Pharmacology | Best Researcher Award

Published on by Health Scientists

Assoc. Prof. Dr. Maryam Tehranipour | Pharmacology | Best Researcher Award

Animal Physiology | Islamic Azad University | Iran

Dr. Maryam Tehranipour is an accomplished Associate Professor in the Department of Biology at the Islamic Azad University, Mashhad, Iran, recognized for her distinguished contributions to the fields of diabetes, metabolic disorders, neurobiology, oxidative stress, and cancer biology. Holding a Ph.D. in Animal Physiology, she has built a dynamic academic and research career integrating cellular physiology, pharmacology, and molecular mechanisms of disease. Her extensive publication record spans a broad spectrum of biomedical investigations, including neuroprotective strategies, natural product pharmacology, nanomedicine, and experimental models of diabetes and neurodegeneration. Dr. Tehranipour’s pioneering studies have elucidated the roles of oxidative damage, angiogenesis, and neuronal regeneration in disease progression and therapeutic recovery, particularly highlighting the potential of bioactive compounds and nanocarrier systems in drug design and targeted therapy. Her collaborative work has advanced understanding of diabetic complications, nerve injury repair, and cancer cell modulation through natural and synthetic agents. Beyond her prolific research output, she has played a significant role in mentoring undergraduate, graduate, and doctoral students, fostering scientific rigor and innovation in physiological research. Her scholarly influence is reflected through her indexed publications, contributions to interdisciplinary research networks, and global collaborations that link physiology, biochemistry, and nanotechnology for translational health impact. Dr. Tehranipour’s scientific endeavors emphasize the integration of experimental biology with clinical relevance, aiming to bridge laboratory discoveries with therapeutic applications. Through her ongoing research, she continues to contribute meaningfully to global biomedical science, particularly in developing sustainable and biologically safe therapeutic interventions addressing chronic and degenerative diseases that pose major public health challenges. She has 238 citations from 53 documents with an h-index of 9.

Profile: Scopus 

Publications

1. The Umbelliprenin-CTAB cellulose nanocrystal delivery system prevents hyperglycemia in diabetic rats by activating the insulin receptor IR/PDK1 pathway. (2025). Scientific Reports. Open access.

2. The effects of N-butanol and ethyl acetate fractions of Ferula asafoetida hydroalcoholic extract on the expression of VEGF and FGF genes in the chorioallantoic membrane of chick embryos. (2025). Journal of Veterinary Research.Open access.

3. Bimetallic-based colorimetric aptasensor for the quantitative analysis of ampicillin using catalytic activity of ZrFe metal–organic framework and terminal deoxynucleotidyl transferase-assisted signal amplification. (2025). Bionanoscience. Open access.

4. The effect of Ziziphora clinopodioides hydroalcoholic extract on the neuronal density and histopathology of the hippocampal area CA2 in streptozotocin-induced Alzheimer’s model in male rats. (2025). Journal of Chemical Health Risks. Open access.

5. A novel alpha-terpineol-loaded niosome formulation coated with hyaluronic acid and evaluation of its anticancer properties in vitro. (2025). Journal of Molecular Liquids. Open access.

Sina Andalib | Pharmacology | Best Researcher Award

Published on by Health Scientists

Assoc. Prof. Dr. Sina Andalib | Pharmacology | Best Researcher Award

correspond author | Zanjan university of medical sciences | Iran

Dr. Sina Andalib is an Associate Professor at the Department of Pharmacology, Pharmacy Faculty, Zanjan University of Medical Sciences, Iran. He earned his Doctor of Veterinary Medicine (DVM) from Tabriz Azad University in 2005, focusing on anti-inflammatory effects of statins, and completed his PhD at Tabriz University of Medical Sciences in 2013, investigating the cardioprotective effects of Atorvastatin in isoproterenol-induced heart failure in rats. Dr. Andalib’s research spans pharmacology, neurodegenerative diseases, drug delivery systems, and natural product therapeutics, with a particular focus on Alzheimer’s disease, Parkinson’s disease, diabetes, and cancer. He has supervised numerous PhD and PharmD theses exploring innovative nanoparticle-based drug delivery, herbal and synthetic compound interventions, and molecular mechanisms underlying neuroprotection and cardioprotection. His work has been published extensively in high-impact international journals including ACS Chemical Neuroscience, Journal of Pharmaceutical Sciences, International Journal of Pharmaceutics, and European Journal of Pharmacology, covering topics such as nanocomposite hydrogels for wound healing, fullerene-based interventions in Alzheimer’s models, and polypharmacological effects of anticancer compounds. Dr. Andalib has contributed to several internationally collaborative projects, including the development of nanocomposites for neuroprotection and polypharmacological studies of anticancer compounds in organoid models. He has received recognition for his scientific contributions in pharmacology and neurotherapeutics and serves on editorial boards of peer-reviewed journals in pharmacology and drug delivery research. In addition to his research, he holds leadership roles at Zanjan University, including Head of the Department of Pharmacology and Toxicology and Head of the Education Development Office, fostering academic development and innovative research in pharmaceutical sciences. He has 751 citations from 39 documents with an h-index of 15.

Profiles: Google Scholar | Scopus | ORCID

Publications

1. Danafar, H., Sharafi, A., Kheiri Manjili, H., & Andalib, S. (2017). Sulforaphane delivery using mPEG–PCL co-polymer nanoparticles to breast cancer cells.

2. Garjani, A., Fathiazad, F., Zakheri, A., Akbari, N. A., Azarmie, Y., Fakhrjoo, A., et al. (2009). The effect of total extract of Securigera securidaca L. seeds on serum lipid profiles, antioxidant status, and vascular function in hypercholesterolemic rats.

3. Barzegar-Jalali, M., Alaei-Beirami, M., Javadzadeh, Y., Mohammadi, G., et al. (2012). Comparison of physicochemical characteristics and drug release of diclofenac sodium–eudragit® RS100 nanoparticles and solid dispersions.

4. Garjani, A., Andalib, S., Biabani, S., Soraya, H., Doustar, Y., & Garjani, A., et al. (2011). Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat.

5. Abedimanesh, N., Asghari, S., Mohammadnejad, K., Daneshvar, Z., et al. (2021). The anti-diabetic effects of betanin in streptozotocin-induced diabetic rats through modulating AMPK/SIRT1/NF-κB signaling pathway.